drugset / Trial / NCT05027139
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is being done to find out if zanidatamab when given with evorpacept (ALX148) is safe and can treat patients with advanced (locally advanced \[inoperable\] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.
Timeline
- Start
- 2021-09-15
- Primary completion
- 2025-08-29
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evorpacept | Protein / enzyme biologic | — | Intravenous |
| Subject | Zanidatamab | Monoclonal antibody | — | Intravenous |